Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3249-3259

  Duvic, Madeleine ^a   Helekar, Bharati ^a   Schulz, Claudia ^a   Cho, Mimi ^a   DiSepio, Dan ^b   Hager, Carina ^a   DiMao, Dominique ^a   Hazarika, Parul ^a   Jackson, Brooke ^a   Breuer McHam, Joan ^a   Young, John ^a   Clayman, Gary ^a   Lippman, Scott M ^a   Chandraratna, Roshandra A S ^b   Robinson, Nancy A ^c   Deucher, Anne ^c   Eckert, Richard L ^c   Nagpal, Sunil ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ALLERGAN INC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RETINOIC ACID RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS; QUANTITATIVE ASSAY; SKIN BIOPSY; SKIN CANCER; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; EPIDERMIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; SKIN PHYSIOLOGY;

EID: 0033887696     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Stoler, A., Kopan, R., Duvic, M., and Fuchs, E. The use of mono-specific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J. Cell Biol., 107: 427-446, 1988.
2. Eckert, R. L., Crish, J. F., Banks, E. B., and Welter, J. F. The epidermis: genes on, genes off. J. Investig. Dermatol., 109: 501-509, 1997.
3. Kanjali, S., and Duvic, M. Cutaneous carcinogenesis: molecular model of cancer development. In: S. Miller (ed.), Cutaneous Oncology. Cambridge: Blackwell Scientific Publications, Inc., 1998.
4. Ziegler, A., Leffel, D. F., Kunala, S., Sharma, H., Gailani, M., Simon, J. A., Halperin, A. J., Baden, H. P., Shapiro. P. E., Bale, A. E., and Brash, D. E. Mutation hotspots due to sunlight in the p53 gene of non-melanoma skin cancer. Proc. Natl. Acad. Sci. USA, 90: 4216-4220, 1993.
5. Glick, A. B., Sporn, M. B., and Yuspa, S. H. Altered regulation of TGF-B1 and TGF-α in primary keratinocytes and papillomas expressing v-Ha-ras. Mol. Carcinog., 4: 210-219, 1991.
6. Gailini, M. R., Bale, S. J., Leffell, D. J., DiGiovanna, J. J., Peck, G. L., Poliak, S., Drum, M. A., Pastakia, B., McBride, O. W., Kase. R., et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell, 69: 111-117, 1992.
7. Ananthaswamy, H. N., Loughlin, S. M., Cox, P., Evans, R. L., Ullrich, S. E., and Kripke, M. L. Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nat. Med., 3: 510-514, 1997.
8. Quinn, A. G., Campbell, C., Healy, E., and Rees, J. L. Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J. Investig. Dermatol., 102: 300-303, 1994.
9. Wiching, C., Shanley, S., Smyth, I., Gillies, S., Negus, K., Graham, S., Suthers, G., Haites, N., Edwards, M., Wainwright, B., and Chenevix-Trench, G. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am. J. Hum. Genet., 60: 21-26, 1997.
10. Scott, R. E., Wilke, M. S., Wille, J. J., Pittelkow, M. R., Hsu, B. M., and Kasperbauer, J. L. Human squamous carcinoma cells express complex defects in the control of proliferation and differentiation. Am. J. Pathol., 133: 374-380, 1988.
11. Duvic, M., Chema, D., Annarella, M., Cho, M., Esgleyes-Ribot, T., Remenyik, E., Ulmer, R., Rapini, R., Sacks, P. G., Clayman, G. L., Davies, P. J. A., and Thacher, S. Keratinocyte transglutaminase expression varies in squamous cell carcinomas. J. Investig. Dermatol., 102: 462-469, 1994.
12. Alkemade, H. A. C., Molhuizen, H. O. F., Vlijmen-Wilems, M. J. J., Haelst, U. J. G. M., and Schalkwijk, J. Differential expression of SKALP/elafin in human epidermal tumors. Am. J. Pathol., 143: 1679-1687, 1993.
13. Baker, B. S., and Fry, L. The immunology of psoriasis. Br. J. Dermatol., 126: 1-9, 1992.
14. Aneskievich, B. J., and Fuchs, E. Terminal differentiation in keratinocytes involves positive and negative regulation by retinoic acid receptors and retinoid X receptors at retinoid response elements. Mol. Cell. Biol., 12: 4862-4871, 1992.
15. Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., and Evans, R. M. Retinoid receptor X interacts with nuclear receptors in retinoic acid, thyroid hormone, and vitamin D3 signalling. Nature (Lond.), 355: 446-449, 1992.
16. Chambon, P. The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog. Horm. Res., 50: 317-332, 1995.
17. Elder, J. T., Astrom, A., Pettersson, U., Tavakkol, A., Griffiths, C. E. M., Krust, A., Kastner, P., Chambon, P., and Voorhees, J. J. Differential regulation of retinoic acid receptors and binding proteins in human skin. J. Investig. Dermatol., 98: 673-679, 1992.
18. Chakravarti, D., LaMorte, V., J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., and Evans, R. M. Role of CBP/P300 in nuclear receptor signalling. Nature (Lond.), 383: 99-102, 1996.
19. Nagpal, S., Athanikar, J., and Chandraratna, R. A. S. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor α. J. Biol. Chem., 270: 923-927, 1995.
20. Saiki, R. K., Scharf, S. , Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A., and Arnheim, N. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science (Washington DC), 230: 1350-1354, 1985.
21. DiSepio, D., Malhotra, M., Chandraratna, R. A. S., and Nagpal, S. Retinoic acid receptor nuclear-factor interleukin 6 antagonism: a novel mechanism of retinoid dependent inhibition of a keratinocyte hyperproliferative differentiation marker. J. Biol. Chem., 272: 25555-25559, 1997.
22. Seitz, C. S., Lin, Q., Deng, H., and Khavari, P. A. Alterations in NF-KB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-KB. Proc. Natl. Acad. Sci. USA, 95: 2307-2313, 1998.
23. Eichner, R., Kahn, M., Capetola, R. J., Gendimenico, G. J., and Mezick, J. A. Effects of topical retinoids on cytoskeletal proteins: implications for retinoid effects on epidermal differentiation. J. Investig. Dermatol., 98: 154-161, 1992.
24. Gunther, S. The therapeutic value of retinoic acid in chronic, acute, guttate, and erythrodermic psoriasis. Dermatology, 89: 515-517, 1973.
25. Ellis, C. N., and Voorhees, J. J. Etretinate therapy. J. Am. Acad. Dermatol., 16: 267-291, 1987.
26. Ranki, A., Lauharanta, J., and Keanerva, L. Effect of etretinate on the distribution of Langerhans cells and T lymphocytes in psoriatic skin. Arch. Dermatol. Res., 276: 102-104, 1984.
27. Lippman, S. M., Lotan, R., and Clayman, G. L. Systemic prevention and treatment of skin cancer. In: R. S. Weber, M. J. Miller, and H. Goepfert (eds.), Basal and Squamous Skin Cancers of the Head and Neck, pp. 351-355. Baltimore: Williams and Wilkins, 1996.
28. Duvic, M., Nagpal, S., Asano, A., and Chandraratna, R. A. S. Molecular mechanisms of Tazarotene action. J. Am. Acad. Dermatol., 37: 85-92, 1997.
29. Weinstein, G., Krueger, G. G., Lowe, N. J., Duvic, M., Friedman, D. J., Jegasothy, B. V., Shmunes, E., Tschen, E. H., Lew-Kaya, D., Lue, J. C., Sefton, J., Gibson, J. R., and Chandraratna, R. A. S. Tazarotene gel, a new retinoid, for topical therapy of psoriasis. Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J. Am. Acad. Dermatol., 37: 85-92, 1997.
30. Duvic, M. The pharmacologic profile of Tazarotene. Cutis, 61: 22-26, 1998.
31. Esgleyes-Ribot, T., Chandraratna, R. A., Lew-Kaya, D. A., Sefton, J., and Duvic, M. Response of psoriasis to a new topical retinoid, AGN 190168. J. Am. Acad. Dermatol., 30: 581-590, 1994.
32. Thacher, S. M., Krasinski, G., Malhotra, M., Duvic, M., Nagpal, S., and Chandraratna. R. A. S. Coordinate regulation of keratinocyte differentiation markers by retinoids in cell culture and in psoriasis. J. Investig. Dermatol., 106: 819, 82, 1996.
33. Duvic, M., Asano, A. T., Hager, C., and Mays, S. The pathogenesis of psoriasis and mechanism of action of Tazarotene. J. Am. Acad. Dermatol., 39: S126-S129, 1998.
34. Peris, K., Fargnoli, M. C., and Chimenti, S. Preliminary observations on the use of topical Tazarotene to treat basal-cell carcinoma. N. Engl. J. Med., 341: 1767-1768, 1999.
35. Nagpal, S., Patel, S., Asano, A. T., Johnson, A. T., Duvic, M., and Chandraratna, R. A. S. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J. Investig. Dermatol., 106: 269-274, 1996.
36. Nagpal, S., Patel, S., Jacobe, H., DiSepio, D., Ghosn, C., Malhotra, M., Teng, M., Duvic, M., and Chandraratna, R. A. S. Tazarotene-induced gene 2 (TIG-2), a novel retinoid responsive gene in skin. J. Investig. Dermatol., 109: 91-95, 1997.
37. Nagpal, S., Thacher, S. M., Patel, S., Friant, S., Malhotra, M., Shafer, J., Krasinski, G., Asano, R. T., Teng, M., Duvic, M., and Chandraratna R. A. S. Negative regulation of two hyperproliferative keratinocyte differentiation markers by an RAR-selective retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differentiation, 7: 1783-1791, 1996.
38. DiSepio, D., Ghosn, C., Eckert, R. L., Deucher, A., Robinson, N., Duvic, M., Chandraratna, R. A. S., and Nagpal, S. Identification and characterization of a retinoid-inducible class II tumor suppressor/antiproliferative gene. Proc. Natl. Acad. Sci. USA, 95: 14811-14815, 1998.
39. Hajnal, A., Klemenz, R., and Schafer, R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene, 9: 419-490, 1994.
40. Szpiere, C., Szpiere, J., Riviere, M., Hajnal, A., Kiess, M., Scharm, B., and Schafer, R. Chromosomal assignment of three rat and human H-rev genes, putative tumor suppressors, down-regulated in malignantly HRAS-transformed cells. Mamm. Genome, 7: 701-793, 1996.
41. Kuchinke, W., Hart, R. P., and Jonakait, G. M. Identification of mRNAs regulated by interferon-γ in cultured rat astrocytes by PCR differential display. Neuroimmunomodulation, 2: 347-355, 1995.
42. di Iasio, M. G., Calin, G., Tibiltti, M. G., Vorchovsky, I., Benediktsson, K. P., Taramelli, R., Barbanti-Brodano, G., and Negrini, M. Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region. Oncogene, 18: 1635-1638, 1999.
43. Murakami, Y., Nobukuni, T., Tamura, K., Maruyama, T., Sekiya, T., Arai, Y., Gomyou, H., Tanigami, A., Ohki, M., Cabin, D., Frischmyer, P., Hunt, P., and Reeves, R. H. Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc. Natl. Acad. Sci. USA, 95: 8153-8157, 1998.
44. Xu, X. C., Clifford, J. L., Hong, W. K., and Lotan, J. R. Detection of nuclear retinoic acid receptor mRNAs in histological tissue sections using non-radioactive in situ hybridization histochemistry. Diagn. Mol. Pathol., 3: 122-131, 1994.
45. Carey, T. Head and neck tumor cell lines. In: Atlas of Human Tumor Cell Lines, pp. 79-120. New York: Academic Press, Inc., 1994.
46. Ritter, S. J., and Davies, P. J. A. Identification of a TGF-B1/BMP4 response element within the mouse tissue transglutaminase gene promoter. J. Biol. Chem., 273: 12798-12806, 1998.
47. Gibson, U. E. M., Heid, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
48. Greaves, M. W., and Weinstein, G. D. Treatment of psoriasis. N. Engl. J. Med., 332: 581-588, 1995.
49. Husman, K., Sers, C., Fietze, E., Mincheva, A., Lichter, P., and Schafer, R. Transcription and translational down-regulation of H-Rev-107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene, 17: 1305-1312, 1998.
50. Herbst, R. A., Gutzmer, R., Matiaske, F., Mommert, S., Casper, U., Kapp, A., and Weiss, J. Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma. Int. J. Cancer, 80: 205-209, 1999.
51. Hampton, G. M., Mannerman, A., Winquist, R., Alavaikko, M., Blanco, G., Taskinen, P. J., Kiviniemi, H., Newsham, I., Cavenee, W. K., and Evans, G. A. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res., 54: 4586-4589, 1994.
52. Gabra, H., Watson, J. E., Taylor, K. J., Mackay, J., Leonard, R. C., Steel, C. M., Porteous, D. J., and Smyth, J. F. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res., 56: 950-954, 1996.
53. Bethwaite, P. B., Koreth, J., Herrington, C. S., and McGee, J. O. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br. J. Cancer, 71: 814-818, 1995.
54. Launonen, V., Stenboack, F., Pusitola, U., Bloigu, R., Huusko, P., Kytola, S., Kauppila, A., and Winquist, R. Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol. Oncol., 71: 299-304, 1998.
55. Lazar, A. D., Winter, M. R., Nogueira, C. P., Larson, P. S., Finnemore, E. N., Dolan, R. W., Fulcihan, N., Chakravarti, A., Zietman, A., and Rosenberg, C. L. Loss of heterogeneity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Clin. Cancer Res., 4: 2787-2793, 1998.
56. Weinberg, R. A. Tumor suppressor genes. Science (Washington DC), 254: 1138-1146, 1991.
57. Brash, D. E., Ziegler, A., Jonason, A. S., Simon, J. A., Kunala, S., and Leffell, D. J. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc., 1: 136-142, 1996.
58. Kanjilal, S., Strom, S., Clayman, G. L., Weber, R. S., El-Naggar, A. K., Kapur, V., Cummings, K. K., Hill, L. A., Spitz, M. R., Kripke, M. L., and Ananthaswamy, H. N. p53 mutations in non-melanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res., 55: 3604-3609, 1995.
59. Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E., and Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Engl. J. Med., 318: 1633-1637, 1988.
60. Lippman, S. M., and Meyskens, F. L. Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol. Ther., 40: 107-122, 1989.
61. Wei, A., Cheng, L., Wang, L., Guo, Z., Strom, S. S., Spitz, M. R., Lippman, S. M., Duvic, M., and Kripke, M. L. Role of DNA repair for UV damage in non-melanoma skin cancer progression. Proc. Am. Assoc. Cancer Res., 39: 477, 1998.